Related Experiment Video
Updated: Oct 12, 2025
04:40
Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
Published on: January 5, 2024
2.7K
A Clot Waveform Analysis Showing a Hypercoagulable State in Patients with Malignant Neoplasms
Mayu Kobayashi1, Hideo Wada2, Shunsuke Fukui1
1Mie Prefectural General Medical Center, Department of Gastroenterology, Yokkaichi 510-0885, Japan.
Journal of Clinical Medicine
|November 27, 2021
Summary
Clot waveform analysis (CWA) of small tissue factor-induced Factor IX activation (sTF/FIXa) shows heightened hypercoagulability in cancer patients. Elevated CWA-sTF/FIXa peak heights indicate a potential risk factor for thrombosis in malignancy.
Area of Science:
- Hematology
- Oncology
- Biochemistry
Background:
- Malignant neoplasms are associated with an increased risk of hypercoagulability and thrombosis.
- Accurate assessment of hypercoagulability is crucial for identifying patients at risk of thrombotic events.
Purpose of the Study:
- To evaluate hypercoagulability in patients with malignant neoplasms using clot waveform analysis (CWA).
- To examine the relationship between hypercoagulability markers and thrombosis in cancer patients.
Main Methods:
- 92 patients with malignant neoplasms underwent clot waveform analysis (CWA)-activated partial thromboplastin time (APTT) and CWA-small amount of tissue factor induced FIX activation (sTF/FIXa) assays.
- Retrospective analysis correlated hypercoagulability markers with the incidence of thrombosis.
Main Results:
- Routine APTT could not effectively identify hypercoagulability in cancer patients.
- Peak heights of CWA-sTF/FIXa were significantly elevated in patients with malignant neoplasms compared to healthy volunteers.
- Higher CWA-sTF/FIXa peak heights were observed in cancer patients with thrombosis versus those without.
Conclusions:
- The peak height of CWA-sTF/FIXa is a sensitive indicator of hypercoagulability in malignant neoplasms.
- Elevated CWA-sTF/FIXa peak height may serve as a significant risk factor for thrombosis in cancer patients.
Related Concept Videos
01:16Clot Retraction and Fibrinolysis
7.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
7.4K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.0K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.0K
01:24Disorders of Hemostasis
1.3K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.3K
01:30Venous Thrombosis IV: Nursing Management
43
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
43
01:30Venous Thrombosis I: Introduction
72
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
72
01:09Coagulation
8.0K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
8.0K